Inovio Pharmaceuticals, Inc. INO
Set alert
2.00 USD +0.11 +5.56%
As of Nov 3, 10:30 AM ET
1.60 Day range 2.04
0.60 52-week range 2.60
- YTD
- +14.66%
- 1 year
- -20.20%
- Open
- 1.87
- Prev close
- 1.89
- Mkt cap
- 206.28M
- Vol
- 20.48M
- Avg vol
- 8.60M
- EPS
- -0.90
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.60
- High
- 2.04
- Forward P/E
- -0.48
- Beta
- 0.83
- Short ratio
- 11.22
- Inst. own
- 33.51%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 6, 2024
- 50-d avg
- 4.56
- 200-d avg
- 8.18
- 1y target
- 10.67
5D chart
Signals (102)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Nov 3, 10:15 AM | 15 minutes ago |
| MACD: Buy Signal | Nov 3, 10:10 AM | 20 minutes ago |
| SMA: Bullish | Nov 3, 10:00 AM | 30 minutes ago |
| RSI: Oversold | Nov 3, 9:30 AM | 1 hour ago |
| SMA: Bearish | Nov 2, 3:05 PM | 19 hours ago |
| SMA: Bearish | Nov 2, 3:05 PM | 19 hours ago |
| SMA: Bullish | Nov 2, 2:50 PM | 19 hours ago |
| SMA: Bearish | Nov 2, 2:45 PM | 19 hours ago |
| SMA: Bullish | Nov 2, 2:35 PM | 19 hours ago |
| SMA: Bearish | Nov 2, 2:20 PM | 20 hours ago |
| SMA: Bullish | Nov 2, 2:00 PM | 20 hours ago |
| SMA: Bearish | Nov 2, 1:55 PM | 20 hours ago |
| SMA: Bearish | Nov 2, 1:55 PM | 20 hours ago |
| SMA: Bullish | Nov 2, 1:25 PM | 21 hours ago |
| RSI: Overbought | Nov 2, 1:25 PM | 21 hours ago |
| SMA: Bearish | Nov 2, 12:50 PM | 21 hours ago |
| MACD: Sell Signal | Nov 2, 10:40 AM | 23 hours ago |
| SMA: Bullish | Nov 2, 9:30 AM | 1 day ago |
| SMA: Bullish | Nov 2, 9:30 AM | 1 day ago |
| MACD: Buy Signal | Nov 2, 9:30 AM | 1 day ago |
Newest 20 of 102.
Analyst view
Consensus: buy
Buy
Price target (mean) 10.67 +434.7% upside
Now 2.00
- Target (low)
- 5.00
- Target (mean)
- 10.67
- Target (high)
- 18.00
Ratings (0m) 6 3 buy · 3 hold · 0 sell
- Strong buy1
- Buy2
- Hold3
- Sell0
- Strong sell0
Recommendation trend
- This month 6
- 1 month ago 6
- 2 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.928 | -1.04 – -0.77 | -5.67 | +83.6% | 30.00K | -70.8% | 5 |
| Next quarter | -1.08 | -1.08 – -1.08 | -1.31 | +17.6% | 100.00K | 0.0% | 1 |
| Current year | -4.39 | -4.71 – -4.09 | -6.09 | +27.9% | 130.60K | -84.3% | 5 |
| Next year | -3.74 | -4.78 – -2.16 | -4.39 | +14.9% | 2.60M | +1889.7% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 18, 2024 | HC Wainwright & Co. | Maintained | Neutral | Neutral |
| Nov 18, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Nov 15, 2024 | RBC Capital | Maintained | Sector Perform | Sector Perform |
| Aug 12, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Aug 9, 2024 | RBC Capital | Maintained | Sector Perform | Sector Perform |
| Jul 15, 2024 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| May 14, 2024 | Stephens & Co. | Initiated | — | Overweight |
| Mar 8, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Mar 7, 2024 | RBC Capital | Reiterated | Sector Perform | Sector Perform |
| Jan 25, 2024 | Oppenheimer | Upgrade | Perform | Outperform |